The court directed the firm to pay Ms Gichuki 10 months’ salary as compensation would be adequate in the circumstances ...

a second-generation anti-histamine and research product of UCB Pharma (Belgium) was launched under a co-marketing agreement. In the same year Glaxo received recognition from the Ministry of ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 ...

The study found that N6LS (VH3810109 or VH109), given every four months in combination with already marketed monthly ...

The global nicotine gums and mints market is projected to reach approximately USD 1,536.2 million by the end of 2024, with a ...

The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial Supply Europe ...

Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

GSK and other pharma companies that have sold ranitidine products over the years have so far been fairly successful in fending off the litigation, with wins in the US and Canada, and the Delaware ...

Shares in GSK fell around 9% this morning ... The company and other pharma groups that have sold ranitidine products over the years have so far been fairly successful in fending off the litigation ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...